Zynerba Pharmaceuticals is engaged in pharmaceutically-produced transdermal cannabinoid therapies for neuropsychiatric disorders. Co. is focused on improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Co. is developing Zygel, the pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting treatment of behavioral symptoms of FXS, ASD and 22q. The ZYNE average annual return since 2015 is shown above.
The Average Annual Return on the ZYNE average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ZYNE average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ZYNE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ZYNE Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
